Moclobemide and selegeline in the treatment of depression in Parkinson's disease.
作者信息
Steur E N, Ballering L A
出版信息
J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):547. doi: 10.1136/jnnp.63.4.547.
Abstract
摘要
相似文献
1
Moclobemide and selegeline in the treatment of depression in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):547. doi: 10.1136/jnnp.63.4.547.
2
Moclobemide for depression.
Drug Ther Bull. 1994 Jan 20;32(1):6-8.
3
Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants.
Acta Psychiatr Scand Suppl. 1990;360:39-41. doi: 10.1111/j.1600-0447.1990.tb05322.x.
4
5
[Moclobemide].
Dtsch Med Wochenschr. 1995 Aug 25;120(34-35):1175-6. doi: 10.1055/s-0029-1234212.
6
[Special aspects of antidepressive therapy].
Nervenarzt. 1994 Mar;65(3 Suppl [speziell]):1-8.
7
Moclobemide (Ro 11-1163) versus imipramine in the treatment of depression.
Acta Psychiatr Scand Suppl. 1990;360:43. doi: 10.1111/j.1600-0447.1990.tb05324.x.
8
Moclobemide.
Lancet. 1994 Mar 12;343(8898):679-80. doi: 10.1016/s0140-6736(94)92680-8.
9
[Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
Nervenarzt. 1996 May;67(5):339-47.
10
Depression in medical illness. Workshop report.
Int Clin Psychopharmacol. 1993 Jan;7(3-4):205-7.
引用本文的文献
1
Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
Int J Mol Sci. 2022 Sep 21;23(19):11059. doi: 10.3390/ijms231911059.
2
Depression in Parkinson's Disease: A Narrative Review.
Cureus. 2022 Aug 7;14(8):e27750. doi: 10.7759/cureus.27750. eCollection 2022 Aug.
3
Chronic Serotonergic Overstimulation Mimicking Panic Attacks in a Patient with Parkinson's Disease Receiving Additional Antidepressant Treatment with Moclobemide.
Case Rep Psychiatry. 2021 Mar 1;2021:8868023. doi: 10.1155/2021/8868023. eCollection 2021.
4
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2157-2164. doi: 10.1007/s00210-020-01933-y. Epub 2020 Jul 3.
5
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2139-2144. doi: 10.1007/s00210-020-01927-w. Epub 2020 Jun 29.
6
, a Forgotten Potential Therapy for Parkinson's Disease?
Mov Disord Clin Pract. 2015 Oct 6;3(1):19-26. doi: 10.1002/mdc3.12242. eCollection 2016 Jan-Feb.
7
Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.
CNS Drugs. 2017 Jul;31(7):551-570. doi: 10.1007/s40263-017-0450-z.
8
Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.
Front Aging Neurosci. 2014 Jul 25;6:180. doi: 10.3389/fnagi.2014.00180. eCollection 2014.
9
Born to yawn? Understanding yawning as a warning of the rise in cortisol levels: randomized trial.
Interact J Med Res. 2012 Sep 20;1(2):e4. doi: 10.2196/ijmr.2241.
10
Striatal mechanisms underlying movement, reinforcement, and punishment.
Physiology (Bethesda). 2012 Jun;27(3):167-77. doi: 10.1152/physiol.00004.2012.
Zotero 插件